Synthetic Blood International, Inc. (OTC BB: SYBD) is a cutting edge biomedical product development company specializing in creating innovative pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, liquid ventilation and implanted glucose sensing. Once these sophisticated products reach the market, they promise to revolutionize treatment of such disease states as diabetes, acute respiratory distress syndrome, stroke, myocardial infarction, and many malignant tumors.

Many of Synthetic Blood's technology platforms are based on the pioneering research of Dr. Leland Clark, developer of the first heart-lung machine and the Clark oxygen and glucose biosensor electrodes.

Backed by a team of industry-experienced scientists and product development engineers, clinicians, regulatory affairs specialists, and manufacturing and marketing experts, Synthetic Blood is vigorously pursuing strategic alliances with major pharmaceutical and medical device companies to market their products worldwide and to identify additional product opportunities in biomedical, commercial and industrial markets.